How annoying are needle vaccinations? Very … But the French billion-euro Biotech DBV Technologies wants to bring a paradigm shift via its Anti-allergy Patch platform! I got to chat with the founder & CEO, Pierre-Henri Benhamou, for more insights.
DBV’s success continues to amaze me. It’s not only close to solving the global peanut and milk allergy problem, it raised over $300M on the NASDAQ, plans to commercialize its patch on its own and is exploring many new therapeutic areas, such as immuno-oncology and intolerances.
The French Biotech is now also going after vaccines with the help of Claire-Anne Siegrist, the head of vaccinology at WHO and at the University Hospital of Geneva. DBV just started a Phase I clinical trial of a toxin produced by BioNet-Asia, a vaccine company based in Bangkok.
I wondered, why source antigens from so far away? As Benhamou told me: “the vaccine market is very special and it’s hard to get access to the antigens”